273 related articles for article (PubMed ID: 17785446)
21. PARP-1 binds E2F-1 independently of its DNA binding and catalytic domains, and acts as a novel coactivator of E2F-1-mediated transcription during re-entry of quiescent cells into S phase.
Simbulan-Rosenthal CM; Rosenthal DS; Luo R; Samara R; Espinoza LA; Hassa PO; Hottiger MO; Smulson ME
Oncogene; 2003 Nov; 22(52):8460-71. PubMed ID: 14627987
[TBL] [Abstract][Full Text] [Related]
22. Alternative modes of binding of poly(ADP-ribose) polymerase 1 to free DNA and nucleosomes.
Clark NJ; Kramer M; Muthurajan UM; Luger K
J Biol Chem; 2012 Sep; 287(39):32430-9. PubMed ID: 22854955
[TBL] [Abstract][Full Text] [Related]
23. Relation between carcinogenesis, chromatin structure and poly(ADP-ribosylation) (review).
Boulikas T
Anticancer Res; 1991; 11(2):489-527. PubMed ID: 1905900
[TBL] [Abstract][Full Text] [Related]
24. Biochemical and Biophysical Methods for Analysis of Poly(ADP-Ribose) Polymerase 1 and Its Interactions with Chromatin.
Chassé MH; Muthurajan UM; Clark NJ; Kramer MA; Chakravarthy S; Irving T; Luger K
Methods Mol Biol; 2017; 1608():231-253. PubMed ID: 28695514
[TBL] [Abstract][Full Text] [Related]
25. Irreversible binding of poly(ADP)ribose polymerase cleavage product to DNA ends revealed by atomic force microscopy: possible role in apoptosis.
Smulson ME; Pang D; Jung M; Dimtchev A; Chasovskikh S; Spoonde A; Simbulan-Rosenthal C; Rosenthal D; Yakovlev A; Dritschilo A
Cancer Res; 1998 Aug; 58(16):3495-8. PubMed ID: 9721847
[TBL] [Abstract][Full Text] [Related]
26. Automodification switches PARP-1 function from chromatin architectural protein to histone chaperone.
Muthurajan UM; Hepler MR; Hieb AR; Clark NJ; Kramer M; Yao T; Luger K
Proc Natl Acad Sci U S A; 2014 Sep; 111(35):12752-7. PubMed ID: 25136112
[TBL] [Abstract][Full Text] [Related]
27. The ways of PARP.
Pirrotta V
Cell; 2004 Dec; 119(6):735-6. PubMed ID: 15607968
[TBL] [Abstract][Full Text] [Related]
28. Domain C of human poly(ADP-ribose) polymerase-1 is important for enzyme activity and contains a novel zinc-ribbon motif.
Tao Z; Gao P; Hoffman DW; Liu HW
Biochemistry; 2008 May; 47(21):5804-13. PubMed ID: 18452307
[TBL] [Abstract][Full Text] [Related]
29. PARP-1 and gene regulation: progress and puzzles.
Kraus WL; Hottiger MO
Mol Aspects Med; 2013 Dec; 34(6):1109-23. PubMed ID: 23357755
[TBL] [Abstract][Full Text] [Related]
30. Transcriptional regulation of mouse mu opioid receptor gene in neuronal cells by poly(ADP-ribose) polymerase-1.
Choi HS; Hwang CK; Kim CS; Song KY; Law PY; Loh HH; Wei LN
J Cell Mol Med; 2008 Dec; 12(6A):2319-33. PubMed ID: 18266974
[TBL] [Abstract][Full Text] [Related]
31. PARP-2 domain requirements for DNA damage-dependent activation and localization to sites of DNA damage.
Riccio AA; Cingolani G; Pascal JM
Nucleic Acids Res; 2016 Feb; 44(4):1691-702. PubMed ID: 26704974
[TBL] [Abstract][Full Text] [Related]
32. A third zinc-binding domain of human poly(ADP-ribose) polymerase-1 coordinates DNA-dependent enzyme activation.
Langelier MF; Servent KM; Rogers EE; Pascal JM
J Biol Chem; 2008 Feb; 283(7):4105-14. PubMed ID: 18055453
[TBL] [Abstract][Full Text] [Related]
33. Binding mode of novel 1-substituted quinazoline derivatives to poly(ADP-ribose) polymerase-catalytic domain, revealed by X-ray crystal structure analysis of complexes.
Matsumoto K; Kondo K; Ota T; Kawashima A; Kitamura K; Ishida T
Biochim Biophys Acta; 2006 May; 1764(5):913-9. PubMed ID: 16631419
[TBL] [Abstract][Full Text] [Related]
34. Crystal structure of the catalytic domain of human PARP2 in complex with PARP inhibitor ABT-888.
Karlberg T; Hammarström M; Schütz P; Svensson L; Schüler H
Biochemistry; 2010 Feb; 49(6):1056-8. PubMed ID: 20092359
[TBL] [Abstract][Full Text] [Related]
35. Identification of domains of poly(ADP-ribose) polymerase for protein binding and self-association.
Buki KG; Bauer PI; Hakam A; Kun E
J Biol Chem; 1995 Feb; 270(7):3370-7. PubMed ID: 7852424
[TBL] [Abstract][Full Text] [Related]
36. Gene therapy for prostate cancer by targeting poly(ADP-ribose) polymerase.
Trofimova I; Dimtchev A; Jung M; Rosenthal D; Smulson M; Dritschilo A; Soldatenkov V
Cancer Res; 2002 Dec; 62(23):6879-83. PubMed ID: 12460902
[TBL] [Abstract][Full Text] [Related]
37. Cooperative targeting of PARP-1 domains to regulate metabolic and developmental genes.
Bamgbose G; Johnson S; Tulin A
Front Endocrinol (Lausanne); 2023; 14():1152570. PubMed ID: 37347109
[TBL] [Abstract][Full Text] [Related]
38. Mutations in the amino-terminal domain of the human poly(ADP-ribose) polymerase that affect its catalytic activity but not its DNA binding capacity.
Trucco C; Flatter E; Fribourg S; de Murcia G; Ménissier-de Murcia J
FEBS Lett; 1996 Dec; 399(3):313-6. PubMed ID: 8985170
[TBL] [Abstract][Full Text] [Related]
39. Identification of lysines 36 and 37 of PARP-2 as targets for acetylation and auto-ADP-ribosylation.
Haenni SS; Hassa PO; Altmeyer M; Fey M; Imhof R; Hottiger MO
Int J Biochem Cell Biol; 2008; 40(10):2274-83. PubMed ID: 18436469
[TBL] [Abstract][Full Text] [Related]
40. DNA-dependent SUMO modification of PARP-1.
Zilio N; Williamson CT; Eustermann S; Shah R; West SC; Neuhaus D; Ulrich HD
DNA Repair (Amst); 2013 Sep; 12(9):761-73. PubMed ID: 23871147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
